IL-22/STAT3-Induced Increases in SLURP1 Expression within Psoriatic Lesions Exerts Antimicrobial Effects against Staphylococcus aureus

PLoS One. 2015 Oct 16;10(10):e0140750. doi: 10.1371/journal.pone.0140750. eCollection 2015.

Abstract

Background: SLURP1 is the causal gene for Mal de Meleda (MDM), an autosomal recessive skin disorder characterized by diffuse palmoplantar keratoderma and transgressive keratosis. Moreover, although SLURP1 likely serves as an important proliferation/differentiation factor in keratinocytes, the possible relation between SLURP1 and other skin diseases, such as psoriasis and atopic dermatitis, has not been studied, and the pathophysiological control of SLURP1 expression in keratinocytes is largely unknown.

Objectives: Our aim was to examine the involvement of SLURP1 in the pathophysiology of psoriasis using an imiquimod (IMQ)-induced psoriasis model mice and normal human epidermal keratinocytes (NHEKs).

Results: SLURP1 expression was up-regulated in the skin of IMQ-induced psoriasis model mice. In NHEKs stimulated with the inflammatory cytokines IL-17, IL-22 and TNF-α, which are reportedly expressed in psoriatic lesions, SLURP1 mRNA expression was significantly up-regulated by IL-22 but not the other two cytokines. The stimulatory effect of IL-22 was completely suppressed in NHEKs treated with a STAT3 inhibitor or transfected with siRNA targeting STAT3. Because IL-22 induces production of antimicrobial proteins in epithelial cells, the antibacterial activity of SLURP1 was assessed against Staphylococcus aureus (S. aureus), which is known to be associated with disease severity in psoriasis. SLURP1 significantly suppressed the growth of S. aureus.

Conclusions: These results indicate SLURP1 participates in pathophysiology of psoriasis by regulating keratinocyte proliferation and differentiation, and by suppressing the growth of S. aureus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoquinolines / pharmacology
  • Animals
  • Antigens, Ly / genetics*
  • Antigens, Ly / metabolism
  • Female
  • Homeostasis / drug effects
  • Humans
  • Imiquimod
  • Interleukin-22
  • Interleukins / pharmacology*
  • Keratinocytes / cytology
  • Keratinocytes / drug effects
  • Keratinocytes / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Psoriasis / chemically induced
  • Psoriasis / genetics
  • Psoriasis / metabolism
  • Psoriasis / microbiology*
  • STAT3 Transcription Factor / metabolism*
  • Skin / drug effects
  • Skin / metabolism
  • Skin / microbiology
  • Staphylococcus aureus / growth & development*
  • Up-Regulation / drug effects*
  • Urokinase-Type Plasminogen Activator / genetics*
  • Urokinase-Type Plasminogen Activator / metabolism

Substances

  • Aminoquinolines
  • Antigens, Ly
  • Interleukins
  • SLURP-1 protein, mouse
  • SLURP1 protein, human
  • STAT3 Transcription Factor
  • Urokinase-Type Plasminogen Activator
  • Imiquimod

Grants and funding

This work was supported in part by JSPS KAKENHI Grant Numbers 15K21370 (Y.M.), 23111006 (H.M.) and 26460692 (S.T.); MEXT KAKENHI Grant Numbers 25293020 (H.M.) and 24590120 (K.K.); MEXT-Supported Program (Grant Number S1411004) for the Strategic Research Foundation at Private Universities 2014-2016 (H.M.); the Smoking Research Foundation (K.K. and H.M.); The Naito Foundation (H.M.); and the Hoansha Foundation (H.M.).